Ipsen Presents Positive Preclinical Oncology Data

Ipsen announced the presentation of new positive preclinical data for two of its early development programs, IPN01203 and IPN60300, at the American Association for Cancer Research congress. IPN01203, a T cell activator generated by Marengo Therapeutics' STAR platform, showed potential to transform care in solid tumors by activating specific T cells. Additionally, Ipsen revealed ITGA2 as the novel target for its antibody-drug conjugate IPN60300, which was identified using Foreseen Biotechnology's platforms and incorporates an innovative linker from Escugen Biotechnology. Preclinical findings for IPN60300 demonstrated pronounced over-expression of ITGA2 across multiple solid tumors and favorable anti-tumor activity. These findings reinforce Ipsen's precision medicine approach and its commitment to addressing unmet needs in oncology.